Ranolazine + Placebo

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Diabetic Peripheral Neuropathic Pain

Conditions

Diabetic Peripheral Neuropathic Pain

Trial Timeline

May 1, 2014 → Feb 8, 2017

NCT ID

NCT02156336

About Ranolazine + Placebo

Ranolazine + Placebo is a approved stage product being developed by Gilead Sciences for Diabetic Peripheral Neuropathic Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT02156336. Target conditions include Diabetic Peripheral Neuropathic Pain.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Peripheral Neuropathic Pain were approved

Approved (20) Terminated (3) Active (0)

✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅Duloxetine + Pregabalin + PlaceboShionogiApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03044964	Approved	UNKNOWN	Jan 10, 2017	Oct 1, 2017	Angina
NCT02829034	Approved	Completed	Jul 1, 2016	Jan 1, 2018	Pulmonary Hypertension
NCT02423265	Approved	Withdrawn	Jun 1, 2015	Mar 1, 2017	Myocardial Ischemia
NCT02147067	Phase 2	Completed	Sep 1, 2014	Jun 1, 2018	Microvascular Angina
NCT02156336	Approved	Terminated	May 1, 2014	Feb 8, 2017	Diabetic Peripheral Neuropathic Pain
NCT02052011	Approved	Completed	Apr 1, 2014	Nov 1, 2015	Microvascular Angina
NCT01948310	Approved	Completed	Dec 1, 2013	Oct 10, 2016	Chronic Stable Angina
NCT01887353	Phase 2	Terminated	Jun 1, 2013	Feb 1, 2014	Atrial Fibrillation
NCT01767987	Phase 2	Terminated	Nov 1, 2012	Apr 1, 2014	Acute Coronary Syndrome
NCT01590979	Pre-clinical	Terminated	Apr 1, 2012	Jun 1, 2015	Atrial Fibrillation New Onset
NCT01558830	Approved	UNKNOWN	Jan 1, 2012	Jul 1, 2013	Chronic Stable Angina
NCT01472185	Phase 3	Completed	Nov 1, 2011	Oct 1, 2013	Type 2 Diabetes Mellitus
NCT01442038	Phase 3	Completed	Oct 1, 2011	Feb 1, 2015	Coronary Artery Disease
NCT01505179	Pre-clinical	Completed	Feb 1, 2011	Jan 1, 2015	Heart Failure With Preserved Ejection Fraction
NCT01352416	Phase 3	Terminated	Sep 1, 2010	Nov 1, 2012	Heart; Dysfunction Postoperative, Cardiac Surgery
NCT01163721	Phase 2	Completed	Jun 1, 2010	Nov 1, 2010	Diabetes Mellitus, Type 2
NCT00832572	Approved	Terminated	Jan 1, 2009	Jun 1, 2009	Coronary Artery Disease
NCT00099788	Phase 3	Completed	Oct 1, 2004	Feb 1, 2007	Myocardial Ischemia

Competing Products

20 competing products in Diabetic Peripheral Neuropathic Pain

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	25
CHF6467 active	Comac Medical	Phase 1/2	22
Ruboxistaurin mesylate	Eli Lilly	Phase 3	40
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	29
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	23
Baricitinib + Placebo	Eli Lilly	Phase 2	35
LY3857210 + Placebo	Eli Lilly	Phase 2	35
UBX1325	Unity Biotechnology	Phase 2	25
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	25
UBX1325	Unity Biotechnology	Phase 1	19
CT-P42 + Eylea	Celltrion	Phase 3	40
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	43
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
DS-5565 + placebo	Daiichi Sankyo	Phase 3	40
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22